HL Financial Services LLC Has $235,000 Holdings in Astrazeneca PLC (AZN)
HL Financial Services LLC reduced its position in Astrazeneca PLC (NYSE:AZN) by 83.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,925 shares of the company’s stock after selling 35,241 shares during the period. HL Financial Services LLC’s holdings in Astrazeneca PLC were worth $235,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of AZN. Meeder Asset Management Inc. purchased a new position in Astrazeneca PLC in the 2nd quarter valued at about $105,000. WFG Advisors LP boosted its position in Astrazeneca PLC by 36.0% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after buying an additional 984 shares during the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in Astrazeneca PLC by 71.2% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after buying an additional 1,769 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Astrazeneca PLC by 18.4% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after buying an additional 846 shares during the last quarter. Finally, Westport Asset Management Inc. purchased a new position in Astrazeneca PLC in the 2nd quarter valued at about $170,000. 14.16% of the stock is owned by institutional investors.
Shares of Astrazeneca PLC (NYSE AZN) traded up $0.34 during trading hours on Wednesday, hitting $33.25. 2,914,200 shares of the company’s stock traded hands, compared to its average volume of 4,841,029. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The firm has a market capitalization of $82,760.00, a price-to-earnings ratio of 7.85, a P/E/G ratio of 2.84 and a beta of 0.79. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.32 earnings per share. Astrazeneca PLC’s revenue was up 9.4% compared to the same quarter last year. sell-side analysts anticipate that Astrazeneca PLC will post 1.93 EPS for the current fiscal year.
A number of research firms have weighed in on AZN. Citigroup Inc. raised shares of Astrazeneca PLC to a “buy” rating in a research report on Wednesday, October 18th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub cut shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. BMO Capital Markets set a $38.00 price target on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Finally, Cowen and Company reaffirmed a “hold” rating and set a $34.00 price target on shares of Astrazeneca PLC in a research report on Friday, July 28th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $34.20.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/hl-financial-services-llc-has-235000-holdings-in-astrazeneca-plc-azn/1704772.html.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.